2030 related articles for article (PubMed ID: 10201020)
1. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
[TBL] [Abstract][Full Text] [Related]
2. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
3. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
Misra M; Webb AT; Reaveley DA; Doherty E; O'Donnell M; Seed M; Brown EA
Adv Perit Dial; 1997; 13():168-73. PubMed ID: 9360675
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.
Lee DM; Knight-Gibson C; Samuelsson O; Attman PO; Wang CS; Alaupovic P
Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103
[TBL] [Abstract][Full Text] [Related]
5. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis.
Yiğitoğlu MR; Polat MF; Akçay F; Ari Z; Uyanik BS; Ozilgili HM
Jpn Heart J; 1997 Jan; 38(1):83-9. PubMed ID: 9186284
[TBL] [Abstract][Full Text] [Related]
6. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
[TBL] [Abstract][Full Text] [Related]
7. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
Kimak E; Solski J; Janicka L; Ksaziek A; Janicki K
Clin Chem Lab Med; 2000 May; 38(5):421-5. PubMed ID: 10952225
[TBL] [Abstract][Full Text] [Related]
8. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
[TBL] [Abstract][Full Text] [Related]
9. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
[TBL] [Abstract][Full Text] [Related]
10. Presence of Apo B48, and relative Apo CII deficiency and Apo CIII enrichment in uremic very-low density lipoproteins.
Atger V; Beyne P; Frommherz K; Roullet JB; Drüeke T
Ann Biol Clin (Paris); 1989; 47(8):497-501. PubMed ID: 2690681
[TBL] [Abstract][Full Text] [Related]
11. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
12. The uremic dyslipidemia: a cross-sectional and longitudinal study.
Avram MM; Goldwasser P; Burrell DE; Antignani A; Fein PA; Mittman N
Am J Kidney Dis; 1992 Oct; 20(4):324-35. PubMed ID: 1415199
[TBL] [Abstract][Full Text] [Related]
13. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
Nishizawa Y; Shoji T; Emoto M; Kawasaki K; Konishi T; Tabata T; Inoue T; Morii H
Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
[TBL] [Abstract][Full Text] [Related]
14. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.
Dieplinger H; Schoenfeld PY; Fielding CJ
J Clin Invest; 1986 Apr; 77(4):1071-83. PubMed ID: 3082933
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
16. Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment.
Wakabayashi Y; Okubo M; Shimada H; Sato N; Koide A; Marumo F; Nakamura H
Metabolism; 1987 Sep; 36(9):815-20. PubMed ID: 3626863
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein A-I Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles.
Bekaert ED; Alaupovic P; Knight-Gibson CS; Franceschini G; Sirtori CR
J Lipid Res; 1993 Jan; 34(1):111-23. PubMed ID: 8445335
[TBL] [Abstract][Full Text] [Related]
18. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease.
Karpe F; Hellénius ML; Hamsten A
Metabolism; 1999 Mar; 48(3):301-7. PubMed ID: 10094104
[TBL] [Abstract][Full Text] [Related]
19. Increased concentrations of Apo B-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure.
Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P
Miner Electrolyte Metab; 1992; 18(2-5):199-202. PubMed ID: 1465058
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Burrell D; Antignani A; Fein PA; Goldwasser P; Mittman N; Avram MM
ASAIO Trans; 1990; 36(3):M331-5. PubMed ID: 2123635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
